BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan

RESEARCH TRIANGLE PARK, N.C., April 03, 2017 -- (Healthcare Sales & Marketing Network) -- BioCryst Pharmaceuticals, Inc. (BCRX) announced today that Mundipharma has obtained regulatory approval of Mundesine® (Forodesine hydrochloride) for the treatment... Biopharmaceuticals, Oncology, Regulatory BioCryst Pharmaceuticals, Mundesine, Forodesine, Peripheral T-Cell Lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news